Aumolertinib With Stereotactic Radiotherapy at Intracranial Oligo-progression in EGFR-Mutant NSCLC With Brain Metastases: Results of a Prospective Phase II Study

Ameile (aumolertinib) - Jiangsu Hansoh Pharma

J. Chen1; M. Fan1; B. Wang1; J. Wen1; H. Li1; Y. Cao2; S. Wang3; H. Yu4; C. Zhou2,5; X. Xu5

Aug 15, 2026